Danni Cao

A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics

Yanan Zhao, Xiaoyu Xu, Na Wen et al. · Scientific Reports · 2017 · 81 citations · Full text

C-Phycocyanin inhibits hepatic gluconeogenesis and increases glycogen synthesis <i>via</i> activating Akt and AMPK in insulin resistance hepatocytes

Zhiheng Ren, Zhifei Xie, Danni Cao et al. · Food & Function · 2018 · 76 citations

Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between <i>in Vitro</i> Agonist Bias and <i>in Vivo</i> Pharmacological Effects

Danni Cao, Peng Huang, Yi-Ting Chiu et al. · ACS Chemical Neuroscience · 2020 · 31 citations · Full text

Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist

Yan Zhou, Kevin B. Freeman, Vincent Setola et al. · Handbook of experimental pharmacology · 2021 · 25 citations · Full text

Molecular Pharmacology, Medicine, Preclinical Studies +10

Alterations of prefrontal cortical microRNAs in methamphetamine self-administering rats: From controlled drug intake to escalated drug intake

Hao-Yue Du, Danni Cao, Ying Chen et al. · Neuroscience Letters · 2015 · 23 citations

Substance Abuse, Psychoactive Drug, Psychiatry +14